Simulations Plus Releases DDDPlus Version 5.0

Release Adds Significant Enhancements to Unique Software Product

Lancaster, CA—April 14, 2016—Simulations Plus, Inc. (NASDAQ: SLP), the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that it has released Version 5.0 of its DDDPlus™ in vitro dissolution experiment simulation software.

Mr. Jim Mullin, product manager for DDDPlus at Simulations Plus, said, “We’re very pleased to announce the release of DDDPlus Version 5.0. This upgrade further extends our lead in this area by adding valuable new functionalities that will enable formulation scientists in both innovator and generic companies, as well as regulatory agencies, to gain insight into the behaviors of various formulations for pharmaceutical dosage forms. Several of the significant enhancements include:

Mr. John DiBella, vice president for marketing and sales for Simulations Plus, added, “When we first released DDDPlus about ten years ago, acceptance was slower than we expected, primarily because the industry did not have any experience with such a tool. Now the program is in use in pharmaceutical companies and regulatory agencies worldwide, and we receive and respond to customer requests to continue to enhance its capabilities. Also, we have begun promoting synergies between DDDPlus and our flagship GastroPlus™ program to assist with formulation optimization, as we believe there is an opportunity to leverage the large GastroPlus user base to drive further adoption of DDDPlus. In addition to the enhancements in version 5.0 that we are announcing today, we are already at work on further expanding the scope of DDDPlus simulations to include long-acting injectable microspheres as part of one of our funded research collaboration agreements with the U.S. Food and Drug Administration.”

About Simulations Plus, Inc.

Simulations Plus, Inc., is a premier developer of drug discovery and development software as well as a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions. The company is a global leader focused on improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical and biotechnology agents. Our software is licensed for and used in the conduct of drug research by major pharmaceutical and biotechnology companies and regulatory agencies worldwide. Our innovations in integrating new and existing science in medicinal chemistry, computational chemistry, pharmaceutical science, biology, and physiology into our software have made us the leading software provider for physiologically based pharmacokinetic modeling and simulation. For more information, visit our website at

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995—With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect,” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the U.S. Securities and Exchange Commission.

For further information:
Simulations Plus, Inc.
42505 10th Street West
Lancaster, CA
93534-7059 USA
CONTACT: investor relations:
Contact: Renee Bouche